Loading...
Continued experience with hematopoietic stem-cell transplantation (HSCT) is clarifying the long-term risk for cardiovascular disease (CVD). Prior data showed that by 25 years after allogeneic HSCT, the cumulative incidence of arterial events was 22% (JW Oncol Hematol Nov 20 2007).
Now, to determine the risk for CVD after either autologous HSCT or allogeneic HSCT, investigators reviewed the records of 1885 patients who underwent a first HSCT for a hematologic malignancy and survived for ≥1 year. The median age of patients at time of transplant was 44.4 years, and the indication for HSCT was lymphoma in 38.6% of patients, leukemia in 38.3%, and myeloma in 15.4%. Results were as follows:
At median follow-up of 5.9 years, new incidence of hyperte…